Hi-Tech Pharmacal Financial Statements
Hi-Tech Pharmacal Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | April |
© 2009 Morningstar, Inc. Financial Data provided by
Hi-Tech Pharmacal Income Statement
| 2008 | 2007 | 2006 | |
|---|---|---|---|
| Revenue ($ mil.) | 62.0 | 58.9 | 78.0 |
| Gross Profit ($ mil.) | 21.5 | 23.2 | 42.2 |
| Operating Income ($ mil.) | (6.8) | (4.0) | 17.6 |
| Total Net Income ($ mil.) | (5.1) | (2.0) | 11.5 |
| Diluted EPS (Net Income) | (0.45) | (0.17) | 0.85 |
Hi-Tech Pharmacal Quarterly Statements
| Quarter Ending Jan 09 | Quarter Ending Oct 08 | Quarter Ending Jul 08 | |
|---|---|---|---|
| Revenue ($ mil.) | 29.4 | 25.1 | 15.8 |
| Gross Profit ($ mil.) | 13.8 | 12.0 | 6.0 |
| Operating Income ($ mil.) | 3.5 | 2.9 | 1.8 |
| Total Net Income ($ mil.) | 2.1 | 1.1 | 1.5 |
| Diluted EPS (Net Income) | 0.18 | 0.09 | 0.13 |
Hi-Tech Pharmacal Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 1.19 | 2.55 | 5.93 |
| Price/Earnings Ratio | 21.93 | 12.55 | 21.55 |
| Price/Book Ratio | 1.30 | 3.29 | 5.70 |
| Price/Cash Flow Ratio | 16.26 | 10.62 | 36.90 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Hi-Tech Pharmacal Financial Ratios
Hi-Tech Pharmacal Competitive Intelligence
| Mylan | Teva Pharmaceuticals USA | Watson Pharmaceuticals | |
|---|---|---|---|
| Annual Sales ($ mil.) | 5,137.6 | 0.0 | 2,535.5 |
| Employees | 15,000 | 1,025 | 5,070 |
| Market Cap ($ mil.) | 4,093.7 | -- | 3,497.6 |
Competitive Landscape